牛牛AI助理已提取核心訊息
John C. Reed, EVP of Innovative Medicine & R&D at Johnson & Johnson, engaged in a transaction involving the company's stock on February 15, 2024. The specific details of the transaction, including the number of shares traded, the nature of the shares, the transaction price, and the total value of the shares, were not disclosed in the announcement. Following the action, the updated number of shares held by Reed was also not provided.
John C. Reed, EVP of Innovative Medicine & R&D at Johnson & Johnson, engaged in a transaction involving the company's stock on February 15, 2024. The specific details of the transaction, including the number of shares traded, the nature of the shares, the transaction price, and the total value of the shares, were not disclosed in the announcement. Following the action, the updated number of shares held by Reed was also not provided.
強生公司創新醫學與研發執行副總裁約翰·裏德於2024年2月15日參與了一項涉及公司股票的交易。公告中未披露交易的具體細節，包括交易的股票數量、股票的性質、交易價格和股票的總價值。行動之後，也沒有提供裏德持有的最新股票數量。
強生公司創新醫學與研發執行副總裁約翰·裏德於2024年2月15日參與了一項涉及公司股票的交易。公告中未披露交易的具體細節，包括交易的股票數量、股票的性質、交易價格和股票的總價值。行動之後，也沒有提供裏德持有的最新股票數量。
有用
沒用